New dialysis gadget aims to clean blood better and boost life quality

NCT ID NCT07656168

Disease control Sponsor: China-Japan Friendship Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special cartridge (pHA130) added to regular dialysis to remove toxins that standard dialysis misses. One hundred adults with kidney failure on maintenance dialysis will be split into two groups: one gets the new cartridge once a week plus standard dialysis twice a week, the other gets standard dialysis three times a week. The goal is to see if the new approach lowers certain toxins and improves quality of life over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: pHA130 hemoadsorption cartridge (a device used during dialysis to remove more toxins)
What this could lead to: If it works, this could offer a better way to filter blood during dialysis, potentially reducing heart problems and improving daily life for people with kidney failure.
What could go wrong: This is a small, early-stage trial with only 100 participants. The new cartridge may not work better than standard dialysis, and there could be side effects like allergic reactions or bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years. * On maintenance hemodialysis for \> 3 months. * Receiving hemodialysis 3 times per week, 4 hours per session. * Standard Kt/V ≥ 1.2. * Voluntarily participates and provides written informed consent. Exclusion Criteria: * Known allergy to the dialyzer or hemoperfusion device. * Platelet count \< 60×10⁹/L. * Serum albumin \< 30 g/L. * 24-hour urine output \> 200 ml. * Inability to achieve a blood flow rate ≥ 200 ml/min. * Coagulation disorders, severe bleeding tendency, or active bleeding. * Pre-dialysis systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg. * Active malignancy. * Active infection, or severe, critical illness of cardiac, pulmonary, hepatic, or nervous systems. * Planned living-donor kidney transplant within the next 6 months. * Current participation in another interventional clinical study, or participation within the past 3 months in an interventional study that may interfere with the present study (e.g., fecal microbiota transplantation); or use of intestinal microecological regulators such as probiotics. * History of unstable angina, myocardial infarction, malignant arrhythmia, cardiac or peripheral vascular surgery, or cerebrovascular accident within the past 8 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESRD (end-stage renal disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESRD (end-stage renal disease) Maintenance hemodialysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New dialysis gadget aims to clean blood better and boost life quality

What the study statuses mean